Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Crescent Biopharma (CBIO) Accumulated Depreciation & Amortization (2016 - 2023)

Crescent Biopharma (CBIO) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $2.5 million as the latest value for Q3 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 7.23% to $2.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $2.5 million, a 7.23% increase, with the full-year FY2022 number at $2.4 million, up 2.74% from a year prior.
  • Accumulated Depreciation & Amortization was $2.5 million for Q3 2023 at Crescent Biopharma, up from $2.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.5 million in Q3 2023 to a low of $1.9 million in Q1 2020.
  • A 4-year average of $2.3 million and a median of $2.3 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 12.03% in 2022; the steepest drop was 2.74% in 2022.
  • Crescent Biopharma's Accumulated Depreciation & Amortization stood at $2.1 million in 2020, then grew by 8.94% to $2.3 million in 2021, then rose by 2.74% to $2.4 million in 2022, then rose by 5.18% to $2.5 million in 2023.
  • Per Business Quant, the three most recent readings for CBIO's Accumulated Depreciation & Amortization are $2.5 million (Q3 2023), $2.5 million (Q2 2023), and $2.4 million (Q4 2022).